UBS raised the firm’s price target on Idexx Laboratories (IDXX) to $750 from $710 and keeps a Neutral rating on the shares. The macro is showing signs of life, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDXX:
- Idexx Laboratories price target raised to $830 from $785 at BTIG
- Idexx Laboratories: Strong Financial Performance and Strategic Advancements Justify Buy Rating
- IDEXX Laboratories Reports Strong Q3 2025 Results
- Idexx Laboratories price target raised to $790 from $700 at BofA
- Idexx Laboratories price target raised to $785 from $745 at Leerink